Riedl O, Fitzal F, Mader N, Dubsky P, Rudas M, Mittlboeck M, Gnant M, Jakesz R
LKH Krems, Department of Surgery, Austria.
Eur J Surg Oncol. 2009 Mar;35(3):264-70. doi: 10.1016/j.ejso.2008.05.007. Epub 2008 Aug 15.
We evaluate the number of surgical two-stage procedures after FSA during breast-conserving therapy (clinical false negative result of FSA) and investigate the influence of microcalcifications, small tumour diameter, neoadjuvant therapy and preoperative biopsy on the clinical false negative rate of FSA.
We retrospectively examined 1016 patients after intraoperative FSA during breast-conserving therapy for breast cancer operated between 1995 and 2001 at the Medical University Vienna.
Only 9% of all patients had to undergo a two-stage operation due to a false negative intraoperative FSA result. The annual local recurrence rate was 1.2% in all patients with no difference between one- and two-stage operated patients. In situ and pT1 lesions were similarly distributed between one-stage and two-stage operated patients. The use of neoadjuvant therapy and stereotactic biopsy (reflecting non-palpable lesions and microcalcifications) were significantly predictive for a false negative FSA result. The use of a preoperative core biopsy, however, reduced the necessity of performing a two-stage operation.
Our study demonstrates that FSA leads to a low rate of two-stage operations. Small lesions and microcalcifications as well as the occurrence of intraductal cancer cells and neoadjuvant therapy increased while preoperative core biopsy reduced the false negative rate of FSA. Overall local recurrence rates after FSA were acceptable.
我们评估保乳治疗期间前哨腋窝淋巴结活检(FSA)后手术两阶段程序的数量(FSA的临床假阴性结果),并研究微钙化、小肿瘤直径、新辅助治疗和术前活检对FSA临床假阴性率的影响。
我们回顾性研究了1995年至2001年在维也纳医科大学接受乳腺癌保乳治疗并进行术中FSA的1016例患者。
所有患者中只有9%因术中FSA假阴性结果而不得不接受两阶段手术。所有患者的年局部复发率为1.2%,一期和二期手术患者之间无差异。原位病变和pT1病变在一期和二期手术患者中的分布相似。新辅助治疗和立体定向活检的使用(反映不可触及病变和微钙化)对FSA假阴性结果具有显著预测性。然而,术前芯针活检的使用减少了进行两阶段手术的必要性。
我们的研究表明,FSA导致两阶段手术率较低。小病变和微钙化以及导管内癌细胞的出现和新辅助治疗增加,而术前芯针活检降低了FSA的假阴性率。FSA后的总体局部复发率是可以接受的。